Search results for: 'Security: The Key to Customer Experience Excellence'

27 Aug 2020  |  Global  |  Market Research

Smart Labs as Key Drivers for the Digital Transformation of Diagnostic Laboratories, 2020

Robotic Automation, Internet of Things (IoT), and Artificial Intelligence (AI) Offering Growth Opportunities for Academic and Commercial Diagnostics Labs

Infographics

×

Key Issues Addressed

Diagnostic academic and commercial research labs suffer from cost pressures, given the ongoing Protecting Access to Medicare Act (PAMA) regulations and reproducibility issues, and are under productivity strain. The recent COVID-19 pandemic leading to increasing test volumes and renewed focus on research and development (R&D) to drive innovation wil...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

Pharmaceutical drug discovery and development processes suffer from declining success rates and a stagnant pipeline. Artificial Intelligence (AI) supported by Big Data could be a key element that can provide an effectual solution. There has been a rapid growth in the data generated within the life sciences and pharmaceutical industries. This stems ...

In this research deliverable, Frost & Sullivan’s analyst team provides bold perspectives and predictions for the Middle East and North Africa (MENA) region’s life sciences industry in 2020. The markets covered include pharmaceuticals, biotechnology, and in-vitro diagnostics. The analysis captures the impact of trends that are expected to transpire ...

12 Aug 2020  |  North America  |  Market Research

New Drug Development for Rare Pediatric Disorders Sustaining High Growth in the Global Orphan Drugs Market, 2019–2025

AI-powered Early Disease Diagnosis and Drug Repurposing will Create New Growth Opportunities

Infographics

×

Key Issues Addressed

Rare diseases have been an increasing area of focus as three waves have converged in recent years: genomic research and innovations becoming mainstream; the forthcoming regulatory policies and financial incentives put in place by the federal agencies; and the increasingly patient-centric and coordinated efforts of patient advocacy groups, caregive...

he global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies...

04 Sep 2018  |  North America  |  Market Research

Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018

Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities

Infographics

×

Key Issues Addressed

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally en...

Traditionally, CMOs have thrived by aggregating demand and delivering benefits of economies of scale. However, with the fading era of blockbuster drugs dispensed to large patient pools and shift to precision medicine, focus on niche indications, and increased R&D in biologics, pharma sponsors are increasingly turning to CMOs as strategic partners i...

This study explores the global immuno-oncology (I-O) markets evolution from 2020 to 2025. An extensive analysis is provided on the growth opportunities envisioned by Frost & Sullivan to help stakeholders leverage their momentum and disrupt the market by offering best-in-class solutions. The study considers oncology agents for which the immune syst...